Drug:
Reaction: ECZEMA
20260101 - 20261231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 26863889 |
US |
3 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 502 | 26864148 |
US |
21 | 1 |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, MIRTAZAPINE, GABAPENTIN, MESALAMINE, |
||||
| 503 | 26864165 |
US |
50 | 1 |
Sleep disorder due to a general medical condition, Arthralgia, Gait disturbance, Dyshidrotic eczema, Eczema, Dermatitis atopic, Dry skin, Eye discharge, Skin exfoliation, Eye inflammation, Dry eye, |
||||
DUPILUMAB, |
||||
| 504 | 26864477 |
US |
68 | 1 |
Eczema, Dry skin, Scar, |
||||
DUPILUMAB, COLCHICINE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ROSUVASTATIN CALCIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 505 | 26864933 |
JP |
69 | |
Eczema, |
||||
EVEROLIMUS, CLARITHROMYCIN, ALOGLIPTIN, DAPAGLIFLOZIN, ROSUVASTATIN, OLOPATADINE, PREGABALIN, ICOSAPENT ETHYL, ICOSAPENT ETHYL CAPSULES, |
||||
| 506 | 26864953 |
US |
53 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 507 | 26864966 |
US |
27 | 2 |
Eczema, Pruritus, Rash, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 508 | 26865830 |
US |
2 | |
Injection site pain, Eczema, Pruritus, |
||||
DUPILUMAB, ADALIMUMAB, |
||||
| 509 | 26865839 |
US |
16 | 2 |
Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 510 | 26866476 |
US |
2 | |
Eczema, |
||||
EVOLOCUMAB, |
||||
| 511 | 26867126 |
JP |
2 | |
Eczema, |
||||
FINERENONE, DAPAGLIFLOZIN, EMPAGLIFLOZIN, |
||||
| 512 | 26867589 |
US |
71 | 2 |
Oral herpes, Injection site pain, Eczema, |
||||
DUPILUMAB, |
||||
| 513 | 26867861 |
US |
36 | 1 |
Eczema, Dry skin, Skin irritation, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 514 | 26857390 |
US |
55 | 1 |
Eczema, Pruritus, |
||||
DUPILUMAB, |
||||
| 515 | 26857563 |
US |
49 | 2 |
Eczema, Rash, Pruritus, Mammoplasty, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, CETIRIZINE HCL, CETIRIZINE, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, FAMOTIDINE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LOSARTAN POTASSIUM, LOSARTAN, ESOMEPRAZOLE MAGNESIUM, TAMOXIFEN CITRATE, ERGOCALCIFEROL, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 516 | 26857743 |
US |
52 | 1 |
Eczema, Pain, Rash erythematous, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 517 | 26857748 |
US |
58 | 1 |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 518 | 26857750 |
US |
44 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 519 | 26857751 |
US |
59 | 1 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 520 | 26858080 |
US |
68 | 2 |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, ALBUTEROL SULFATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, LORATADINE, LORATADINE TABLET, ADALIMUMAB, MESALAMINE, MAGNESIUM, MONTELUKAST SODIUM, MONTELUKAST, PROGESTERONE, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, VITAMIN C, ERGOCALCIFEROL, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
| 521 | 26858089 |
US |
1 | 1 |
Eczema, Rash erythematous, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 522 | 26858337 |
US |
2 | |
Dry skin, Pruritus, Rash, Eczema, |
||||
DUPILUMAB, BIOTIN, PANCRELIPASE, DICYCLOMINE HYDROCHLORIDE, FLUDROCORTISONE ACETATE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LOPERAMIDE HYDROCHLORIDE, DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, MIDODRINE HYDROCHLORIDE, MINOXIDIL, MINOXIDIL FOAM 5% (WOMENS), MIRTAZAPINE, ONDANSETRON HYDROCHLORIDE, BEROTRALSTAT HYDROCHLORIDE, FAMOTIDINE, PRAVASTATIN SODIUM, SERTRALINE HYDROCHLORIDE, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, |
||||
| 523 | 26858367 |
US |
1 | |
Eczema, |
||||
DUPILUMAB, |
||||
| 524 | 26858603 |
US |
30 | 2 |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 525 | 26858607 |
US |
2 | |
Eczema, Rash, Feeling abnormal, Tremor, Headache, |
||||
DUPILUMAB, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, ALBUTEROL SULFATE, AMMONIUM LACTATE, BIOTIN, FENOFIBRATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, METRONIDAZOLE, METRONIDAZOLE TOPICAL, MONTELUKAST SODIUM, MONTELUKAST, OXYBUTYNIN CHLORIDE, PRAVASTATIN SODIUM, SERTRALINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 526 | 26858610 |
US |
5 | 2 |
Skin infection, Skin exfoliation, Eczema, Pruritus, Dry skin, |
||||
DUPILUMAB, ALBUTEROL SULFATE, POLYETHYLENE GLYCOL 3350, SENNOSIDES 8.6 MG TABLETS, SENNOSIDES, SENNA LEAF, SENNA, CETIRIZINE HYDROCHLORIDE, |
||||
| 527 | 26859002 |
US |
62 | 2 |
Inappropriate schedule of product administration, Eczema, Swelling, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 528 | 26859012 |
US |
29 | 1 |
Pharyngitis streptococcal, Eczema, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 529 | 26859018 |
US |
14 | 2 |
Eczema, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 530 | 26859021 |
US |
43 | 1 |
Rash macular, Eczema, |
||||
DUPILUMAB, MONTELUKAST, |
||||
| 531 | 26859034 |
US |
51 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 532 | 26859387 |
US |
50 | 1 |
Eczema, Rash pruritic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 533 | 26859409 |
US |
61 | 2 |
Rash, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 534 | 26859413 |
US |
11 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 535 | 26859428 |
US |
51 | 2 |
Eczema, |
||||
ABATACEPT, |
||||
| 536 | 26859724 |
JP |
59 | 2 |
Myelosuppression, Malignant neoplasm progression, Hypothyroidism, Red blood cell count increased, Platelet count decreased, Proteinuria, Eczema, Malaise, Hypertension, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 537 | 26859840 |
US |
71 | 1 |
Sleep disorder due to a general medical condition, Eczema, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 538 | 26859880 |
US |
3 | 1 |
Eczema, Pruritus, Dry skin, Skin haemorrhage, Scratch, |
||||
DUPILUMAB, |
||||
| 539 | 26860014 |
US |
62 | 1 |
Eczema, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 540 | 26860054 |
US |
28 | 2 |
Eczema, |
||||
TRALOKINUMAB-LDRM, |
||||
| 541 | 26860105 |
US |
59 | 2 |
Eczema, Sleep disorder, Loss of personal independence in daily activities, Mood altered, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 542 | 26860262 |
US |
1 | |
Eczema, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 543 | 26860265 |
US |
30 | 2 |
Asthenia, Pain, Eczema, Product dose omission issue, |
||||
DUPILUMAB, FLUCONAZOLE, METHIMAZOLE, PROPRANOLOL HYDROCHLORIDE, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 544 | 26860283 |
US |
38 | 1 |
Eczema, Skin exfoliation, Intentional dose omission, Injection site pruritus, Injection site warmth, |
||||
DUPILUMAB, |
||||
| 545 | 26860285 |
US |
17 | 1 |
Eczema, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 546 | 26860289 |
US |
61 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 547 | 26860290 |
US |
58 | 2 |
Eczema, Rash, |
||||
DUPILUMAB, |
||||
| 548 | 26860293 |
US |
3 | 2 |
Dermatitis atopic, Pruritus, Eczema, Rebound effect, Rash erythematous, Butterfly rash, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 549 | 26860317 |
US |
77 | 2 |
Eczema, Dry skin, Skin irritation, Pruritus, |
||||
DUPILUMAB, DUPILUMAB, PREDNISONE, |
||||
| 550 | 26860323 |
US |
30 | 2 |
Eczema, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 551 | 26860379 |
US |
64 | 2 |
Nasopharyngitis, Eczema, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 552 | 26860392 |
US |
57 | 2 |
Eczema, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 553 | 26860715 |
US |
1 | |
Administration site paraesthesia, Administration site pain, Drug ineffective, Eczema, Condition aggravated, Expired product administered, |
||||
CRISABOROLE, |
||||
| 554 | 26861046 |
US |
32 | 2 |
Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 555 | 26861049 |
US |
1 | |
Eczema, Erythema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 556 | 26861421 |
JP |
1 | |
Eczema, |
||||
FINERENONE, |
||||
| 557 | 26861572 |
US |
24 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 558 | 26861583 |
US |
64 | 2 |
Cataract, Nephrolithiasis, Sepsis, Respiratory disorder, Lung disorder, Restless legs syndrome, Pain in extremity, Visual impairment, Sleep disorder, Weight increased, Anxiety, Eczema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DIPHENHYDRAMINE HYDROCHLORIDE, BENZONATATE, BIOTIN, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, CALCIUM, COLCHICINE, ROFLUMILAST, EPINEPHRINE, ESCITALOPRAM OXALATE, ESCITALOPRAM, FLUTICASONE PROPIONATE, IRON, LEVALBUTEROL TARTRATE, MAGNESIUM, MONTELUKAST SODIUM, MONTELUKAST, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, PREDNISONE, TOPIRAMATE, ERGOCALCIFEROL, ALPRAZOLAM, AZITHROMYCIN DIHYDRATE, |
||||
| 559 | 26861883 |
US |
2 | 2 |
Eczema, |
||||
DUPILUMAB, AMOXICILLIN, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
| 560 | 26862349 |
US |
14 | 2 |
Eczema, Pruritus, Skin discolouration, Product dose omission issue, |
||||
DUPILUMAB, MINERAL OIL, |
||||
| 561 | 26862532 |
US |
4 | 1 |
Eczema, Therapeutic response shortened, Erythema, Pruritus, Dry skin, Skin fissures, Pain, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 562 | 26852222 |
US |
62 | 1 |
Sleep disorder, Eczema, Pruritus, Skin lesion, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 563 | 26852369 |
US |
2 | 1 |
Eczema, Pruritus, Insomnia, |
||||
DUPILUMAB, |
||||
| 564 | 26852376 |
US |
22 | 1 |
Eczema, Eye inflammation, |
||||
DUPILUMAB, |
||||
| 565 | 26852388 |
US |
4 | 2 |
Erythema, Eczema, |
||||
DUPILUMAB, |
||||
| 566 | 26852596 |
US |
56 | 1 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 567 | 26852853 |
US |
20 | 1 |
Eczema, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 568 | 26852876 |
US |
1 | |
Herpes zoster, Eczema, |
||||
DUPILUMAB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, GABAPENTIN, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, TAMSULOSIN HYDROCHLORIDE, |
||||
| 569 | 26852897 |
US |
70 | 1 |
Eczema, Pruritus, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 570 | 26852906 |
US |
2 | |
Eczema, Erythema, Pruritus, |
||||
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 571 | 26853158 |
US |
18 | 2 |
Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 572 | 26853198 |
US |
77 | 2 |
Erythema, Skin abrasion, Scratch, Eczema, Pruritus, Middle insomnia, Rash, |
||||
DUPILUMAB, |
||||
| 573 | 26853655 |
US |
31 | 1 |
Eczema, Conjunctivitis, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 574 | 26853748 |
US |
54 | 2 |
Eczema, Pruritus, Rash macular, Pain, |
||||
DUPILUMAB, |
||||
| 575 | 26854134 |
US |
27 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 576 | 26854163 |
US |
1 | |
Rash, Eczema, |
||||
DUPILUMAB, |
||||
| 577 | 26854176 |
US |
19 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 578 | 26854364 |
US |
70 | 1 |
Influenza like illness, Chills, Eczema, Skin discolouration, Hypersensitivity, |
||||
MELOXICAM, RITUXIMAB, |
||||
| 579 | 26854541 |
US |
32 | 2 |
Dermatitis, Eczema, Pruritus, Injection site bruising, Oropharyngeal pain, Upper-airway cough syndrome, Sleep disorder due to a general medical condition, Product use in unapproved indication, |
||||
DUPILUMAB, PROGESTERONE, |
||||
| 580 | 26854809 |
US |
2 | |
Cutaneous T-cell lymphoma, Dry skin, Eczema, Productive cough, Condition aggravated, Rhinorrhoea, Abdominal pain upper, Rash, Headache, |
||||
CODEINE SULFATE, |
||||
| 581 | 26854884 |
US |
20 | 2 |
Eczema, Urticaria, |
||||
DUPILUMAB, |
||||
| 582 | 26854902 |
US |
1 | 1 |
Blister, Hand-foot-and-mouth disease, Eczema, Erythema, Skin irritation, Pruritus, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 583 | 26854911 |
US |
47 | 1 |
Eczema, |
||||
DUPILUMAB, |
||||
| 584 | 26854914 |
US |
4 | 2 |
Eczema, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 585 | 26855248 |
CA |
32 | 2 |
Colostomy, Pruritus, Eczema, Condition aggravated, Fatigue, Inappropriate schedule of product administration, |
||||
| 586 | 26855547 |
US |
26 | 2 |
Eczema, Pruritus, Loss of personal independence in daily activities, Mood altered, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 587 | 26855607 |
US |
2 | |
Dermatitis atopic, Eczema, Erythema, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 588 | 26856003 |
US |
3 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 589 | 26856237 |
US |
69 | 2 |
Eczema, Nasopharyngitis, Inappropriate schedule of product administration, Oropharyngeal pain, Nasal congestion, Pruritus, Paraesthesia, Skin exfoliation, Haemorrhage, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 590 | 26856285 |
US |
27 | 1 |
Eczema, Mood altered, |
||||
TRALOKINUMAB-LDRM, |
||||
| 591 | 26856313 |
US |
||
Pruritus, Discomfort, Blister, Rash papular, Eczema, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 592 | 26856314 |
US |
55 | 1 |
Nodule, Initial insomnia, Loss of personal independence in daily activities, Eczema, Pruritus, |
||||
TRALOKINUMAB-LDRM, |
||||
| 593 | 26856326 |
US |
25 | 1 |
Bronchitis, Rhinorrhoea, Eczema, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 594 | 26856356 |
US |
62 | 2 |
Eczema, Sleep disorder, Mood altered, |
||||
TRALOKINUMAB-LDRM, |
||||
| 595 | 26856362 |
US |
37 | 2 |
Eczema, Loss of personal independence in daily activities, Mood altered, |
||||
TRALOKINUMAB-LDRM, |
||||
| 596 | 26857116 |
US |
70 | |
Eczema, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 597 | 26857149 |
US |
47 | 2 |
Eczema, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 598 | 26857232 |
US |
38 | 2 |
Eczema, |
||||
DUPILUMAB, |
||||
| 599 | 26857235 |
US |
48 | 1 |
Eczema, |
||||
DUPILUMAB, UPADACITINIB, |
||||
| 600 | 26857238 |
US |
1 | |
Eczema, Dry skin, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30